Clinical Scorecard: Influence of Pre-Transplant Diabetes and Obesity on Acute Graft-Versus-Host Disease, Relapse Rates, and Mortality Following Allogeneic Hematopoietic Cell Transplantation: Insights from the EBMT Transplant Complications Working Party

At a Glance

Key Highlights

• Pre-transplant obesity (BMI ≥ 30 kg/m2) and diabetes (requiring pharmacologic treatment) are associated with metabolic and inflammatory changes that may influence acute GvHD severity.
• Registry studies show inconsistent associations between obesity or diabetes and acute GvHD incidence, but obesity is more consistently linked to increased non-relapse mortality.
• Recent EBMT data (2016–2020) provide updated insights on the prevalence and impact of pre-transplant diabetes and obesity on transplant outcomes in a large adult cohort.

Guideline-Based Recommendations

Diagnosis

• Assess pre-transplant diabetes status using treatment requirements (insulin or oral hypoglycemics, excluding diet alone).
• Calculate BMI from pre-transplant height and weight to identify obesity (BMI ≥ 30 kg/m2).
• Grade acute GvHD according to Keystone criteria; classify chronic GvHD as limited or extensive per established criteria.

Management

• Consider pre-transplant diabetes and obesity as comorbidities potentially influencing transplant outcomes.
• Monitor and manage metabolic and inflammatory status pre- and post-transplant to potentially mitigate GvHD risk.
• Use reduced intensity/non-myeloablative conditioning regimens increasingly in older or comorbid patients, including those with diabetes or obesity.

Monitoring & Follow-up

• Monitor for acute GvHD development and grade post-transplant, especially in patients with pre-existing diabetes or obesity.
• Track overall survival, relapse incidence, and non-relapse mortality with attention to comorbidity status.
• Perform landmark analyses for survival after grade II–IV acute GvHD occurrence.

Risks

• Pre-transplant obesity and diabetes may increase risk of non-relapse mortality.
• Pre-transplant diabetes may be associated with higher GvHD-related mortality despite unclear impact on acute GvHD incidence.
• Metabolic comorbidities can exacerbate inflammatory responses, potentially worsening transplant complications.

Patient & Prescribing Data

Adults undergoing first allogeneic HCT for hematological malignancies with documented pre-transplant diabetes or obesity

Prevalence of pre-transplant diabetes was 4.4% and obesity 3.9% (BMI ≥ 35 kg/m2) in the EBMT cohort; treatment regimens and donor types were adjusted for in outcome analyses to assess impact on GvHD and mortality

Clinical Best Practices

• Incorporate comprehensive pre-transplant assessment of metabolic comorbidities including diabetes and obesity.
• Use standardized criteria for GvHD diagnosis and grading to enable consistent outcome evaluation.
• Adjust transplant conditioning intensity based on patient comorbidities to optimize outcomes.
• Employ multivariable risk modeling including diabetes and obesity status to inform prognosis and patient counseling.
• Ensure informed consent includes discussion of potential increased risks related to metabolic comorbidities.

References

• EBMT Transplant Complications Working Party study on diabetes and obesity impact
• Keystone criteria for acute GvHD grading
• Chronic GvHD classification criteria